Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 22;13(9):260.
doi: 10.3390/ph13090260.

Adenosine Signaling in Autoimmune Disorders

Affiliations
Review

Adenosine Signaling in Autoimmune Disorders

Giulia Magni et al. Pharmaceuticals (Basel). .

Abstract

The molecular components of the purinergic system (i.e., receptors, metabolizing enzymes and membrane transporters) are widely expressed in the cells of the immune system. Additionally, high concentrations of adenosine are generated from the hydrolysis of ATP in any "danger" condition, when oxygen and energy availability dramatically drops. Therefore, adenosine acts as a retaliatory metabolite to counteract the nucleotide-mediated boost of the immune reaction. Based on this observation, it can be foreseen that the recruitment with selective agonists of the receptors involved in the immunomodulatory effect of adenosine might represent an innovative anti-inflammatory approach with potential exploitation in autoimmune disorders. Quite surprisingly, pro-inflammatory activity exerted by some adenosine receptors has been also identified, thus paving the way for the hypothesis that at least some autoimmune disorders may be caused by a derailment of adenosine signaling. In this review article, we provide a general overview of the roles played by adenosine on immune cells with a specific focus on the development of adenosine-based therapies for autoimmune disorders, as demonstrated by the exciting data from concluded and ongoing clinical trials.

Keywords: CD39; CD73; IB-MECA; adenosine receptors; autoimmunity; methotrexate; multiple sclerosis; psoriasis; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of Ado receptor expression and functions on innate immunity (orange text) and acquired immunity (purple text) cells. Red and blue arrows represent functions that are reduced and enhanced, respectively, by Ado binding to the different receptor subtypes. ATP-metabolizing enzymes CD73 and CD39 are also shown, which cooperate in the generation of extracellular Ado (red dots) through ATP (yellow dots) hydrolysis, thus shifting the balance towards an immunosuppressive environment. Both CD39 and CD73 are highly expressed by Tregs and Bregs, which act as functional regulators for anti-inflammatory and immunosuppressive action during inflammation/infection. See text for details. Created with BioRender.com.

References

    1. Bouma M.G., van den Wildenberg F.A., Buurman W.A. The anti-inflammatory potential of adenosine in ischemia-reperfusion injury: Established and putative beneficial actions of a retaliatory metabolite. Shock. 1997;8:313–320. doi: 10.1097/00024382-199711000-00001. - DOI - PubMed
    1. Antonioli L., Fornai M., Blandizzi C., Pacher P., Haskó G. Adenosine signaling and the immune system: When a lot could be too much. Immunol. Lett. 2019;205:9–15. doi: 10.1016/j.imlet.2018.04.006. - DOI - PubMed
    1. Hoebe K., Janssen E., Beutler B. The interface between innate and adaptive immunity. Nat. Immunol. 2004;5:971–974. doi: 10.1038/ni1004-971. - DOI - PubMed
    1. Green H., Chan T. Pyrimidine starvation induced by adenosine in fibroblasts and lymphoid cells: Role of adenosine deaminase. Science. 1973;182:836–837. doi: 10.1126/science.182.4114.836. - DOI - PubMed
    1. Giblett E.R., Anderson J.E., Cohen F., Pollara B., Meuwissen H.J. Adenosine deaminase deficiency in two patients with severely impaired cellular immunity. Lancet. 1972;2:1067–1069. doi: 10.1016/S0140-6736(72)92345-8. - DOI - PubMed